No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Moroctocog Alfa is a recombinant human coagulation factor VIII (FVIII) used to treat and prevent bleeding episodes in people with hemophilia A. It is a type of hematological drug, which is used to treat blood-related disorders. Moroctocog Alfa is a genetically engineered version of the naturally occurring FVIII protein, which is missing or deficient in people with hemophilia A. It is administered intravenously or subcutaneously to replace the missing FVIII protein and help the blood clot normally.
Moroctocog Alfa is approved for use in adults and children with hemophilia A. It is used to prevent and treat bleeding episodes, as well as to reduce the frequency of bleeding episodes. It is also used for routine prophylaxis to prevent bleeding episodes in people with severe hemophilia A.
Some companies in the Moroctocog Alfa market include Novo Nordisk, Pfizer, and Bayer. Show Less Read more
